Skip to main content
SpringerLink
Log in

Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C

  • Clinical Trials Report
  • Lung Neoplasms, Non-Small-Cell Lung Cancer, Chemotherapy, Palliative Treatment, Performance Status
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

In a series of 46 symptomatic patients with metastatic, stage IV, non-small-cell lung cancer (NSCLC), we used a three-drug combination with cisplatin (120 mg/m2), vinblastine (6 mg/m2) and mitomycin-C (6 mg/m2) (PVM), repeated every 3 weeks. After two courses, we observed that none of the patients had achieved a complete response; 33% (15/46) had partial response (95% confidence limits: 19.2–46.8); 39% (18/46), stable disease and 28% (13/46), progressive disease. Median response duration was 14.0 weeks (range, 4–36.7), median time to progression 22.4 weeks (range, 7–44.4), and median survival time 26.4 weeks (range, 1–103). WHO grade III–IV myelotoxicity occurred in 15.2% of the courses administered, affecting 39.5% of patients, and severe nephrotoxicity was observed in 9.3% of patients. No toxic death occurred. The post-treatment KPS score increased in 7 patients with partial response (47%), 4 with stable disease (22%) and 1 with progressive disease (8%), while it decreased in 3 patients with partial response (20%), 3 with stable disease (17%) and 10 with progressive disease (77%). In all, KPS increased in 12/46 cases (26%). However, no statistically significant difference was observed when the KPS score before and after treatment was compared in the total group of patients or when it was compared in responders and in non-responders. After chemotherapy, there was complete disappearance of at least one symptom in 27.1% of cases and improvement in 27.1%. Overall, major symptom control occurred in 54.3% of cases, with a median palliation time lasting 10 weeks (range, 4–32). Patients with partial remission and stable disease achieved symptomatic palliation in 90% and 55.5% of cases, respectively. When we compared the palliation rate between responders and non-responders, a significant difference was noted (Chi-square test:P<0.05). Although our schedule did not produce a higher objective response rate and the KPS score was not significantly improved, the symptom palliation appeared worthwhile considering the highly unfavourable prognosis of the patients investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bakker W, Oosteron AT van, Aaronson Nk, Breukelen FJM van, Bins MC, Hermans J (1986) Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol 22: 963–970

    Google Scholar 

  2. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602–1613

    Google Scholar 

  3. Bunn PA (1989) The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol 16 [Suppl 6]: 10–21

    Google Scholar 

  4. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, Fatati G (1991) A randomized trial of alternating chemotherapy versus best supportive care in advanced non-smallcell lung cancer. J Clin Oncol 9: 1453–1461

    Google Scholar 

  5. Chang AY, Kuebler JP, Tormey DC, Anderson S, Pandya KJ, Borden EC, Davis TE, Trump DL (1986) Phase II evaluation of combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer. Cancer 51: 54–59

    Google Scholar 

  6. Cullen MH, Joshi R, Chetiyawardana A, Woodroffe C (1988) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58: 359–361

    Google Scholar 

  7. Donnadieu N, Paesmans M, Sculier J (1991) Chemotherapy of non-small-cell lung cancer according to disease extent. A meta-analysis of the literature. Lung Cancer 7: 243–252

    Google Scholar 

  8. Folman RS, Rosman M (1988) The role of chemotherapy in nonsmall-cell lung cancer: the community perspective. Semin Oncol 5 [Suppl 4]: 16–21

    Google Scholar 

  9. Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW (1990) High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of Northern California Oncology Group. Cancer Chemother Pharmacol 27: 243–247

    Google Scholar 

  10. Gandara DR, Crowley J, Livingstone RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP (1993) Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southern Oncology Group. J Clin Oncol 11: 873–878

    Google Scholar 

  11. Ganz PA, Figlin RA, Haskel CM, Lo Soto N, Siau J (1989) Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 63: 1271–1278

    Google Scholar 

  12. Gralla R (1990) New directions in non-small cell lung cancer. Semin Oncol 17 [Suppl 7]: 14–19

    Google Scholar 

  13. Gralla R, Casper ES, Kelsen DP (1981) Cisplatin plus vindesine combination chemotherapy for advanced carcinoma of the lung cancer. A randomized trial investigating two dosage schedules: Ann Intern Med 95: 414–420

    Google Scholar 

  14. Gralla R, Kris MG, Potanovich LM, Marks LA, Heelan RT (1989) Enhancing the safety and efficacy of the MVP regimen (mitomycin + vinblastine + cisplatin) in 100 patients with inoperable nonsmall cell lung cancer. Proc ASCO 8: 227

    Google Scholar 

  15. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866–1872

    Google Scholar 

  16. Hardly JR, Noble T, Smith IE (1989) Symptom relief with moderate dose chemotherapy mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 60: 764–766

    Google Scholar 

  17. Kris MG, Gralla RJ, Potanovich LM, Marks LD, Heelan RT (1990) Assessment of pretreatment symptoms and improvement after edam + mitomycin + vinblastine (EMV) in patients (PTS) with inoperable non-small cell lung cancer (NSCLC). Proc ASCO 9: 229

    Google Scholar 

  18. Martoni A, Guaraldi M, Casadio M, Busutti L, Pannuti F (1992) A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer (NSCLC). Ann Oncol 3: 864–866

    Google Scholar 

  19. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Google Scholar 

  20. Mountain CF (1989) Value of the new TNM staging system for the clinical staging of lung cancer. Chest 97: 935–947

    Google Scholar 

  21. Report to the Medical Research Concil by its Lung Cancer Working Party (1991) Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63: 265–270

  22. Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C, Ribelles N, Culubret M (1990) A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 65: 1692–1699

    Google Scholar 

  23. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creeh RH, Mason BA, Joss RA, Vogl S (1986) A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4: 14–22

    Google Scholar 

  24. Soquet PJ, Chouvin F, Boissel JP, Cellerin R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tummarello D, Williams J, Woods BL, Bernard JP (1993) Polichemotherapy in advanced nonsmall cell lung cancer: a meta-analysis. Lancet 342: 19–21

    Google Scholar 

  25. Tummarello D, Guidi F, Porfiri E, Raspugli M, Isidori P, Fatati G, Biscottini B, Cellerino R (1988) Chemotherapy versus supportive care in advanced non-small cell lung cancer: a prospective randomized trial. Lung Cancer 4: A 123

    Google Scholar 

  26. Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton R, Etzell PS, Marschke RF, Kardinal CG, Maksymiuk AW, Ebbert LP, Tazelaar HD, Witrak GA (1992) A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer 70: 2281–2287

    Google Scholar 

  27. Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1990) A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608–611

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ospedale di Torrette, University of Ancona, I-60020, Ancona, Italy

    Diego Tummarello, Francesco Graziano & Riccardo Cellerino

  2. Department of Pneumology, Hospital of Pesaro, USL 3, I-61100, Pesaro, Italy

    Pierpaolo Isidori

Authors
  1. Diego Tummarello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierpaolo Isidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Cellerino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tummarello, D., Graziano, F., Isidori, P. et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother. Pharmacol. 35, 249–253 (1995). https://doi.org/10.1007/BF00686556

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686556

Key words

Search

Navigation